Phibro Animal Health (NASDAQ:PAHC) Sets New 12-Month High – Still a Buy?

Phibro Animal Health Co. (NASDAQ:PAHC)’s share price hit a new 52-week high during trading on Tuesday . The stock traded as high as $26.55 and last traded at $26.14, with a volume of 82337 shares changing hands. The stock had previously closed at $25.77.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Barclays lifted their target price on shares of Phibro Animal Health from $20.00 to $22.00 and gave the stock an “underweight” rating in a research note on Monday, February 10th. Morgan Stanley lifted their price objective on shares of Phibro Animal Health from $20.00 to $25.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 17th. Finally, StockNews.com downgraded Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 6th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $21.00.

Phibro Animal Health Price Performance

The firm has a market capitalization of $930.29 million, a PE ratio of 47.85, a P/E/G ratio of 0.51 and a beta of 0.52. The firm’s fifty day moving average price is $22.21 and its 200 day moving average price is $22.07. The company has a current ratio of 3.20, a quick ratio of 1.37 and a debt-to-equity ratio of 2.99.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.14. Phibro Animal Health had a return on equity of 25.35% and a net margin of 1.75%. As a group, equities analysts forecast that Phibro Animal Health Co. will post 1.95 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 26th. Investors of record on Wednesday, March 5th will be paid a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 2.09%. The ex-dividend date of this dividend is Wednesday, March 5th. Phibro Animal Health’s dividend payout ratio is currently 100.00%.

Institutional Investors Weigh In On Phibro Animal Health

A number of institutional investors have recently modified their holdings of PAHC. Geode Capital Management LLC increased its stake in shares of Phibro Animal Health by 5.7% during the third quarter. Geode Capital Management LLC now owns 507,469 shares of the company’s stock worth $11,430,000 after purchasing an additional 27,201 shares in the last quarter. Barclays PLC raised its holdings in shares of Phibro Animal Health by 25.7% during the third quarter. Barclays PLC now owns 143,337 shares of the company’s stock valued at $3,228,000 after acquiring an additional 29,271 shares during the last quarter. Algert Global LLC boosted its stake in shares of Phibro Animal Health by 521.1% in the third quarter. Algert Global LLC now owns 71,335 shares of the company’s stock worth $1,606,000 after acquiring an additional 59,850 shares during the last quarter. FMR LLC increased its position in shares of Phibro Animal Health by 22.7% during the third quarter. FMR LLC now owns 39,310 shares of the company’s stock worth $885,000 after purchasing an additional 7,270 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its stake in Phibro Animal Health by 3.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 24,336 shares of the company’s stock valued at $548,000 after purchasing an additional 729 shares during the last quarter. 99.34% of the stock is currently owned by institutional investors and hedge funds.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.